N-Cadherin Monoclonal Antibody (Clone RM259)

N-cadherin is an adhesion molecule that mediates the formation of adherens junctions and regulates tissue formation and neural development.^1,2 It is a transmembrane glycoprotein that contains an extracellular cadherin domain that forms cell-cell interactions, a transmembrane domain, and a cytoplasmic domain that interacts with a variety of adaptor proteins, including β-catenin, to influence cytoskeletal dynamics.¹ N-cadherin is widely expressed in the nervous system, as well as in osteoblasts, endothelial cells, and stromal cells, and localizes to the cell surface where it forms adherens junctions that stabilize FGFR, activating ERK/MAPK signaling and promoting cell survival and migration.² N-cadherin cell surface expression is regulated by endocytosis and is required for neuronal patterning and regulation of FGFR activity.³ Upregulation of N-cadherin is a key feature of the epithelial-mesenchymal transition (EMT), a process that promotes tumorigenesis and cancer metastasis.¹ Tumor N-cadherin levels are increased in patients with a variety of epithelial or non-epithelial solid cancers, including lung, breast, or skin, and are associated with decreased overall survival.⁴ Cayman’s N-Cadherin Rabbit Monoclonal Antibody (Clone RM259) can be used for Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Cao, Z.-Q., Wang, Z., and Leng, P. Aberrant N-cadherin expression in cancer. Biomed. Pharmacother. 118, 109320 (2019).

2. Loh, C.-Y., Chai, J.Y., Tang, T.F., et al. The E-Cadherin and N-Cadherin switch in Epithelial-to-Mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells 8(10), 1118 (2019).

3. Kowalczyk, A.P., and Nanes, B.A. Adherens junction turnover: regulating adhesion through cadherin endocytosis, degradation, and recycling. Subcell. Biochem. 60, 197-222 (2012).

4. Mrozik, K.M., Blaschuk, O.W., Cheong, C.M., et al. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer 18(1), (2018).